Table 1

Patient characteristics stratified by CYP2C19*2 genotype

CharacteristicCYP2C19 *1/*1 (n=737)CYP2C19 *1/*2 (n=260)CYP2C19 *2/*2 (n=27)p Value
Age (years)64±1165±1064±120.582
BMI (kg/m2)27±427±428±40.249
Male gender561 (76.1)189 (72.7)20 (74.1)0.541
Current smoking9 (1.2)3 (1.2)0 (0)0.974
Hypertension559 (75.9)205 (78.8)23 (85.2)0.368
Diabetes mellitus136 (18.5)49 (18.8)5 (18.5)0.993
LVEF <45%108 (14.7)43 (16.5)6 (22.2)0.463
Renal failure57 (7.7)21 (8.1)2 (7.4)0.981
Medication
 Clopidogrel LD (300 mg/600 mg)299 (42.0)/62 (8.7)105 (41.7)/16 (6.3)17 (68.0)/1 (4.0)0.079
 PPI195 (27.2)51 (19.9)9 (36.0)0.035
 CCB/amlodipine*241 (33.8)/127 (17.8)96 (37.9)/55 (21.7)10 (38.5)/7 (26.9)0.469/0.234
 Statin581 (80.7)211 (82.7)22 (81.5)0.771
 β-blocker5569 (78.6)201 (79.1)17 (63.0)0.144
Laboratory parameters
 Platelet count (109/l)269±74280±97246±640.049
 Mean platelet volume (fl)7.4±0.97.5±1.07.7±1.10.123
Procedural characteristics
 No. of stents implanted1.6±0.81.6±0.81.5±0.80.934
 LAD356 (48.3)120 (46.2)14 (51.9)0.766
 Drug-eluting stent474 (64.7)154 (59.9)19 (70.4)0.302
  • Continuous variables are presented as mean±SD, dichotomous variables as counts (%).

  • * Amlodipine was shown to be the calcium channel blocker associated with HPR in a previously published sub-analysis of POPular.5

  • BMI, body mass index; LAD, left anterior descending artery; LD, loading dose either 300 mg or 600 mg clopidogrel; LVEF, left ventricular ejection fraction; MPV, mean platelet volume; PLT, platelet count; PPI, proton pump inhibitor.